文献速递乳腺癌放疗放疗物理与技术

放射敏感性基因特征与PD-L1状态预测浸润性乳腺癌放疗结局

A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
PubMed 文献 · Radiother Oncol · 2017-06-01

基于TCGA数据库中1045例浸润性乳腺癌患者,按放射敏感性基因特征分为放射敏感(RS)与放射抵抗(RR)两组,并按CD274 mRNA中位值分为PD-L1高/低组。仅在接受放疗时,RS组无复发生存(RFS)优于RR组(HR 0.45,95%CI 0.25-0.81,p=0.008);RS与PD-L1高表达独立相关,PD-L1高组中RS组RFS更优(HR 0.37,95%CI 0.16-0.87,p=0.022)。

要点

  • 仅放疗条件下RS组RFS优于RR组(HR 0.45,95%CI 0.25-0.81,p=0.008)。
  • RS组CD274 mRNA表达显著高于RR组(p<0.001),RS与PD-L1高表达独立相关。
  • PD-L1高组中RS组RFS优于RR组(HR 0.37,95%CI 0.16-0.87,p=0.022)。

核心结论

  • 放射敏感性基因特征与PD-L1状态是预测浸润性乳腺癌放疗临床结局的重要因素。
  • 二者可能用于筛选可从放疗联合抗PD1/PD-L1治疗中获益的患者。

研究设计与样本

  • 基于TCGA数据库浸润性乳腺癌数据,验证放射敏感性相关基因特征并分析PD-L1状态。
  • 选取1045例患者,按预后以共识聚类算法分为放射敏感(RS)与放射抵抗(RR)两簇。
  • 以CD274 mRNA表达中位值作为PD-L1替代指标,将患者分为PD-L1高/低组。

主要发现

  • 仅在接受放疗时,RS组较RR组无复发生存(RFS)风险降低(HR 0.45,95%CI 0.25-0.81,p=0.008)。
  • RS组与PD-L1高组独立相关,RS组CD274 mRNA表达显著高于RR组(p<0.001)。
  • PD-L1高组中,多因素分析显示RS组较RR组RFS更优(HR 0.37,95%CI 0.16-0.87,p=0.022)。

关键数值与推荐

  • 以CD274 mRNA表达中位值划分PD-L1高/低组。
  • RS与RR分组采用共识聚类算法,依据患者预后确定。

临床怎么用

  • 放射敏感性基因特征联合PD-L1状态或可用于预判浸润性乳腺癌放疗结局。
  • 可能辅助筛选适合放疗联合抗PD1/PD-L1治疗的患者。

局限性

  • 研究基于TCGA数据库,结论需外部数据验证。
  • PD-L1状态以CD274 mRNA表达中位值替代,非蛋白水平检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We investigated the link between the radiosensitivity gene signature and programmed cell death ligand 1 (PD-L1) status and clinical outcome in order to identify a group of patients that would possibly receive clinical benefit of radiotherapy (RT) combined with anti-PD1/PD-L1 therapy. MATERIAL AND METHODS: We validated the identified gene signature related to radiosensitivity and analyzed the PD-L1 status of invasive breast cancer in The Cancer Genome Atlas (TCGA) dataset. To validate the gene signature, 1045 patients were selected and divided into two clusters using a consensus clustering algorithm based on their radiosensitive (RS) or radioresistant (RR) designation according to their prognosis. Patients were also stratified as PD-L1-high or PD-L1-low based on the median value of CD274 mRNA expression level as surrogates of PD-L1. RESULTS: Patents assigned to the RS group had decreased risk of recurrence-free survival (RFS) rate than patients in the RR group by univariate analysis (HR 0.45, 95% CI 0.25-0.81, p=0.008) only when treated with RT. The RS group was independently associated with the PD-L1-high group, and CD274 mRNA expression was significantly higher in the RS group (p<0.001) than the RR group. In the PD-L1-high group, the RS group was associated with better RFS compared to the RR group (HR 0.37, 95% CI 0.16-0.87, p=0.022) in multivariate analysis. The level of PD-L1 expression may represent the immunogenicity of tumors, and thus, we speculated that the PD-L1-high group had more immunogenic tumors, which could be more sensitive to radiation-induced immunologic cell death. CONCLUSION: We first evaluated the predictive value of the radiosensitivity gene signature and described a relationship with this radiosensitivity gene signature and PD-L1. The radiosensitivity gene signature and PD-L1 status were important factors for prediction of the clinical outcome of RT in patients with invasive breast cancer and may be used for selecting patients who will benefit from RT combined with anti-PD1/PDL1 therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jang BS, Kim IA. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. Radiother Oncol. 2017. PMID: 28579282. doi:10.1016/j.radonc.2017.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。